New approach in cancer therapy with innovative mechanism-of-action for ferroptosis induction

A team of researchers led by Dr. Marcus Conrad from Helmholtz Munich discovered a novel anti-cancer drug, called icFSP1, which sensitizes cancer cells to ferroptosis. Ferroptosis is characterized by the iron-dependent oxidative destruction of cellular membranes, which is counteracted by ferroptosis suppressor protein-1 (FSP1), one of the guardians of ferroptosis. Although FSP1 has been considered as an attractive drug target for cancer therapy, in vivo efficacious FSP1 inhibitors have been lacking.
Source: World Pharma News - Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news